Interesting article on seeking alpha (check the yahoo page for AEGR). From the article:
There have been four different insiders selling Aegerion and there have not been any insiders buying Aegerion during the past 30 days. Two of these four insiders decreased their holdings by more than 10%. Aegerion has an insider ownership of 0.70%.
I think what they know, is that a company with $7M in revenue should not have a market cap of $2.40B. The drug launch, whenever that is in the future, does not mean profits roll in the next day. And we're hearing although approved, there may be some issues with the drug, I don't know what they are, I'm still researching that.